🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. KEYTRUDA 25 mg/mL concentrate for solution for infusion, ivonescimab, Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin 10 mg/ml concentrate for solution for infusion, Abraxane 5 mg/ml powder for dispersion for infusion., Pazenir 5 mg/ml powder for dispersion for infusion., ALIMTA 500 mg powder for concentrate for solution for infusion

    Summit Therapeutics

    Metastatic Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  2. KHK4827

    KYOWA KIRIN AUSTRALIA PTY LTD

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  3. KIOVIG 100 mg/ml solution for infusion, TECVAYLI 90 mg/mL solution for injection, TECVAYLI 10 mg/mL solution for injection, KIOVIG 100 mg/ml solution for infusion

    Takeda

    Primary infection prophylaxis for secondary immunodeficiency (SID) in patients with multiple myeloma (MM) receiving B cell maturation antigen (BCMA)-directed bispecific (BsAb) therapy

    phase 3 small molecule active

    1 trial

  4. KP415 oral capsule

    ZEVRA THERAPEUTICS, INC.

    ADHD

    phase 3 small molecule completed

    2 trials

  5. KYV-101

    Kyverna Therapeutics

    Lupus Nephritis, Systemic Sclerosis, Myasthenia Gravis, Rheumatoid Arthritis, Stiff Person Syndrome

    phase 3 small molecule active

    1 trial

  6. Kamada-AAT for Inhalation, Placebo for “Kamada-AAT for Inhalation”

    Kamada BioPharma Limited at Fieldfisher LLP

    Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% ≤ FEV1 ≤ 80% of predicted; FEV1/SVC ≤ 70%), and with no history of two or more moderate or one or more severe exacerbations of COPD during the past year.

    phase 3 small molecule active

    1 trial

  7. KarX-EC, KarX-EC, KarX-EC matching placebo, KarXT, KarXT, KarX-EC, KarX-EC, KarXT matching placebo, KarXT, KarXT

    Bristol-Myers Squibb Australia Pty Ltd

    Mild to moderate Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  8. KarX-EC, KarXT, KarX-EC matching placebo, KarX-EC, KarXT, KarXT, KarXT matching placebo, KarXT, KarX-EC, KarX-EC

    Bristol-Myers Squibb Australia Pty Ltd

    Mild to moderate Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  9. Ketamine

    United Therapeutics Europe Ltd

    Chronic Pain

    phase 3 small molecule completed

    1 trial

  10. Ketamine Hydrochloride

    Camp4 Therapeutics Corp

    Suicide

    phase 3 small molecule terminated

    1 trial

  11. Ketamine Hydrochloride

    United Therapeutics Europe Ltd

    Traumatic Injury

    phase 3 small molecule active

    1 trial

  12. Ketanest-S 25 Multi-dose, oplossing voor injectie 25 mg/ml

    Disc Medicine

    Non-psychotic therapy resistant unipolar depression

    phase 3 small molecule active

    1 trial

  13. Keverprazan Hydrochloride tablets + high dose amoxicillin

    The First People's Hospital of Lianyungang

    Helicobacter Pylori Infection Helicobacter Pylori Eradication Patient Education

    phase 3 small molecule active

    1 trial

  14. Khalas dates

    United Therapeutics Europe Ltd

    Diabetes Mellitus

    phase 3 other completed

    1 trial

  15. L-leucovorin

    United Therapeutics Europe Ltd

    Colorectal Cancer

    phase 3 small molecule completed

    1 trial

  16. LARONIDASE, OTL-203, -, RITUXIMAB, FLUDARABINE, BUSULFAN, PLERIXAFOR

    Orchard Therapeutics (Netherlands) B.V.

    Mucopolysaccharidosis type I, Hurler Syndrome

    phase 3 small molecule active

    1 trial

  17. LDX 30 mg

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    1 trial

  18. LETROZOLE, ANASTROZOLE, CAPECITABINE, PACLITAXEL, CAPECITABINE, Verzenios 50 mg film-coated tablets, FULVESTRANT

    Ningbo Cancer Hospital

    Patients with untreated metastatic Estrogen Receptor positive (ER+), Human Epidermal Growth Factor Receptor-2 negative (HER2-) breast cancer with visceral involvement

    phase 3 small molecule active

    1 trial

  19. LETROZOLE, ELACESTRANT, ANASTROZOLE, EXEMESTANE, TAMOXIFEN, ELACESTRANT

    Stemline Therapeutics B.V.

    Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence

    phase 3 small molecule active

    1 trial

  20. LGP PURE CBD 200, caprylic/capric triglyceride liquid

    The George Institute

    Patients with stage I, II, III hormone-receptor positive (HR+) breast cancer (BC) receiving adjuvant aromatase inhibitors (AI) and presenting AI-related musculoskeletal pain (reported average joint pain score of ≥ 4 out of 10 on the Brief Pain Inventory)

    phase 3 small molecule active

    1 trial

  21. LGP PURE CBD 200, caprylic/capric triglyceride liquid

    The George Institute

    Patients with stage I, II, III hormone-receptor positive (HR+) breast cancer (BC) receiving adjuvant aromatase inhibitors (AI) and presenting AI-related musculoskeletal pain (reported average joint pain score of ≥ 4 out of 10 on the Brief Pain Inventory)

    phase 3 small molecule active

    1 trial

  22. LIBTAYO 350 mg concentrate for solution for infusion.

    Partner Therapeutics Limited

    Patients with resected stage II-IIIA non-small cell lung cancer (NSCLC) with PD-L1 expression ≥1%

    phase 3 small molecule active

    1 trial

  23. LOPERAMIDE , Ultra-Levura 250 mg cápsulas duras, Placebo to Saccharomyces boulardii

    Biocodex

    Non-constipated Irritable Bowel Syndrome (IBS)

    phase 3 small molecule active

    1 trial

  24. LY2189265

    United Therapeutics Europe Ltd

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources